All 48 NHS radiotherapy providers in England are expected to offer SABR for localized prostate cancer, with the first centers starting next week.
SABR delivers treatment in five doses over a fortnight instead of at least 20 standard radiotherapy sessions, a shift the NHS says can cut side effects and the burden of repeated hospital visits.
Around 17,500 men in England are diagnosed each year with low- or intermediate-risk prostate cancer and could be offered the option; NHS modelling suggests about 3,500 may choose it.
The expansion targets the UK’s most common male cancer, which sees more than 55,000 diagnoses annually and about 12,300 deaths, as the NHS moves the treatment beyond trial settings.
As this new cancer therapy rolls out, are its hidden risks being ignored?
This 'godsend' cancer therapy is here, but who are the thousands of men who won't qualify?
The UK champions a cancer breakthrough, but its research funding is collapsing. Is this progress sustainable?
Revolutionizing Prostate Cancer Treatment: Nationwide Implementation of 5-Session SABR by NHS England
Overview
NHS England has launched a new 5-session Stereotactic Ablative Radiotherapy (SABR) treatment for prostate cancer, marking a major step forward in cancer care. SABR uses advanced technology to deliver highly targeted radiation from multiple angles, allowing a high dose to the tumor while protecting healthy tissues. This approach, known as hypofractionation, means patients need fewer treatment sessions. The rollout is supported by significant investment in new equipment and guided by clear eligibility criteria and robust policies. Together, these efforts aim to ensure effective implementation and equitable access to this innovative, efficient treatment across the country.